Hepatitis B burden could place China at an elevated risk of liver cancer 11-Jul-2023 By Isabel Cameron Hepatitis B (HBV) has long been known as one of the biggest risk factors for primary liver cancer.
KU Leuven spin-off AstriVax raises €30m to build vaccine platform 25-Aug-2022 By Jane Byrne Closing on €30m, vaccine producer, AstriVax, has raised the largest amount of seed capital in the history of KU Leuven spin-offs.
GSK flags new data suggesting a stark decline in routine adult vaccinations in the US 23-Mar-2021 By Jane Byrne The pharma company and the CDC are recommending that adults continue routine vaccination during the COVID-19 pandemic to reduce future vaccine-preventable disease (VPD) outbreaks and overall strain on the healthcare system.
Primate deaths cause stock plummet for Arrowhead as RNAi PhII trials halted by FDA 18-Nov-2016 By Dani Bancroft The US FDA has halted a trial of a candidate Hepatitis B infection drug developed by Arrowhead Pharma Inc. after primate deaths in a toxicology study.
Abivax's IPO to fund HIV and hep B pipeline before potential Big Pharma deal 06-Jul-2015 By Dan Stanton In France’s largest ever biotech IPO, Abivax has raised €58m ($64m) to continue developing its HIV and Hep B candidates.